novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Rivaroxabano, múltiplas doses, múltiplas indicações

17 Abril 2021

. · CHALLENGES BAYER TIPS 6 DANIEL CALDEIRA

Dupla inibição trombótica. Para quem ?

17 Abril 2021
0

11th Challenges in Cardiology

17 Abril 2021
0

-->